Biovian and 3P Biopharmaceuticals combined companies to create a new pan-European independent CDMO named 3PBIOVIAN. A spokesperson says the new group will offer end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for Drug Substance and Drug Product, from preclinical to clinical development and commercial phases.
3PBIOVIAN plans to leverage its manufacturing sites in Pamplona-Noáin (Spain) and Turku (Finland) as well as its commercial office in Boston to address an extensive array of customer needs, according to Dámaso Molero Sánchez (former 3P CEO) who now will serve as group CEO. He is supported by Antti Nieminen (former Biovian CEO), now deputy CEO, Heidi Suuronen as CFO, and Elena Erroba as CCO.
Forty-year track record
“We are thrilled about this opportunity and the new chapter for our combined companies,” says Nieminen. “The highly synergistic and comprehensive service offering allows 3PBIOVIAN to further enhance its competitiveness in the biologics CDMO market. With a combined 40-year track record and a commitment to quality, both companies have always prioritized customer-centric service.”
“I am very delighted about this exciting new stage, which is nothing more than the consequence of the enormous and excellent work done by Biovian and 3P over the years,” adds Molero Sanchez. “The combination of technology, capabilities and most importantly, the quality of the human team, positions us a leader in the highly dynamic international market for the development and manufacturing of advanced therapies.”
The board of directors includes Uwe Gottschalk, former CSO and CTO of Lonza Pharma and before that group vice president at Sartorius; Stefan Stoffel, based in Switzerland, formerly part of the executive committee and COO at Lonza; and Tom Ransohoff, based in the U.S., formerly technical head of biologics at Resilience, following its acquisition of 4th Dimension Bioprocess, a company he co-founded.
